DK3892295T3 - Individualiserede vacciner mod cancer - Google Patents
Individualiserede vacciner mod cancer Download PDFInfo
- Publication number
- DK3892295T3 DK3892295T3 DK21168360.2T DK21168360T DK3892295T3 DK 3892295 T3 DK3892295 T3 DK 3892295T3 DK 21168360 T DK21168360 T DK 21168360T DK 3892295 T3 DK3892295 T3 DK 3892295T3
- Authority
- DK
- Denmark
- Prior art keywords
- against cancer
- vaccines against
- individualized vaccines
- individualized
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/70—Machine learning, data mining or chemometrics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/002576 WO2012159643A1 (en) | 2011-05-24 | 2011-05-24 | Individualized vaccines for cancer |
EP2012000006 | 2012-01-02 | ||
EP18199105.0A EP3473267B1 (en) | 2011-05-24 | 2012-05-23 | Individualized vaccines for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3892295T3 true DK3892295T3 (da) | 2023-05-15 |
Family
ID=46148823
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12723117.3T DK2714071T3 (da) | 2011-05-24 | 2012-05-23 | Individualiserede vacciner mod cancer |
DK21168360.2T DK3892295T3 (da) | 2011-05-24 | 2012-05-23 | Individualiserede vacciner mod cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12723117.3T DK2714071T3 (da) | 2011-05-24 | 2012-05-23 | Individualiserede vacciner mod cancer |
Country Status (22)
Country | Link |
---|---|
US (3) | US10738355B2 (da) |
JP (5) | JP6444171B2 (da) |
CN (3) | CN103608033B (da) |
AU (4) | AU2012261237B2 (da) |
BR (1) | BR112013029834A8 (da) |
CA (1) | CA2836494C (da) |
DK (2) | DK2714071T3 (da) |
ES (3) | ES2946072T3 (da) |
FI (1) | FI3892295T3 (da) |
HR (2) | HRP20230443T1 (da) |
HU (3) | HUE062102T2 (da) |
LT (3) | LT3892295T (da) |
MX (2) | MX360823B (da) |
NZ (2) | NZ742420A (da) |
PL (1) | PL3892295T3 (da) |
PT (3) | PT3473267T (da) |
RS (2) | RS64230B1 (da) |
RU (1) | RU2670745C9 (da) |
SG (2) | SG193553A1 (da) |
SI (2) | SI3473267T1 (da) |
WO (1) | WO2012159754A2 (da) |
ZA (1) | ZA201306944B (da) |
Families Citing this family (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
EP2364368B1 (en) | 2008-11-07 | 2014-01-15 | Sequenta, Inc. | Methods of monitoring conditions by sequence analysis |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
DK2387627T3 (da) | 2009-01-15 | 2016-07-04 | Adaptive Biotechnologies Corp | Adaptiv immunitetsprofilering og fremgangsmåder til at frembringe monoklonale antistoffer |
EP2446052B1 (en) | 2009-06-25 | 2018-08-08 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
BR112013029834A8 (pt) | 2011-05-24 | 2022-10-18 | Biontech Ag | vacinas individualizadas para câncer |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
US9279159B2 (en) | 2011-10-21 | 2016-03-08 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
CA2858070C (en) | 2011-12-09 | 2018-07-10 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
ES2904816T3 (es) | 2012-02-27 | 2022-04-06 | Becton Dickinson Co | Composiciones para recuento molecular |
DK2823060T3 (da) | 2012-03-05 | 2018-05-28 | Adaptive Biotechnologies Corp | Bestemmelse af forbundne immunreceptorkæder fra hyppighedsafstemte underenheder |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
ES2582554T3 (es) | 2012-05-08 | 2016-09-13 | Adaptive Biotechnologies Corporation | Composiciones y método para medir y calibrar el sesgo de la amplificación en reacciones de PCR multiplexadas |
CN104662171B (zh) * | 2012-07-12 | 2018-07-13 | 普瑟姆尼股份有限公司 | 个性化癌症疫苗和过继免疫细胞治疗 |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
DK2901341T3 (da) | 2012-09-28 | 2019-07-15 | Univ Connecticut | Identifikation af tumorbeskyttelsesepitoper til behandling af cancere |
DK2904111T3 (da) | 2012-10-01 | 2018-03-12 | Adaptive Biotechnologies Corp | Immunkompetence evaluering af adaptiv immunreceptor diversitet og klonalitet karakterisering |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
US10155031B2 (en) * | 2012-11-28 | 2018-12-18 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
WO2014093186A1 (en) * | 2012-12-12 | 2014-06-19 | Garvin Alex M | Non-invasive detection of colorectal neoplasia using circular consensus sequencing |
EP2946345B1 (en) | 2013-01-17 | 2024-04-03 | Personalis, Inc. | Methods and systems for genetic analysis |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
SG10201707394PA (en) * | 2013-03-15 | 2017-10-30 | Adaptive Biotechnologies Corp | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
WO2014168874A2 (en) * | 2013-04-07 | 2014-10-16 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
WO2015013461A2 (en) * | 2013-07-26 | 2015-01-29 | Sequenta, Inc. | Cancer vaccination with antigen evolution |
GB2546833B (en) | 2013-08-28 | 2018-04-18 | Cellular Res Inc | Microwell for single cell analysis comprising single cell and single bead oligonucleotide capture labels |
EP3039161B1 (en) | 2013-08-30 | 2021-10-06 | Personalis, Inc. | Methods and systems for genomic analysis |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
GB2535066A (en) | 2013-10-03 | 2016-08-10 | Personalis Inc | Methods for analyzing genotypes |
CN105745528A (zh) | 2013-10-07 | 2016-07-06 | 赛卢拉研究公司 | 用于以数字方式对阵列上的特征进行计数的方法和系统 |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
DK3077539T3 (da) | 2013-12-02 | 2018-11-19 | Personal Genome Diagnostics Inc | Fremgangsmåde til evaluering af minoritetsvariationer i en prøve |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CA2932798C (en) * | 2013-12-06 | 2022-09-20 | The Broad Institute, Inc. | Formulations for neoplasia vaccines |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
AU2015227054A1 (en) | 2014-03-05 | 2016-09-22 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
EP3132059B1 (en) | 2014-04-17 | 2020-01-08 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
JP7044551B2 (ja) | 2014-09-10 | 2022-03-30 | ジェネンテック, インコーポレイテッド | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
US11338026B2 (en) | 2014-09-10 | 2022-05-24 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
WO2016053339A1 (en) | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
ES2784343T3 (es) | 2014-10-29 | 2020-09-24 | Adaptive Biotechnologies Corp | Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras |
EP3212808B1 (en) | 2014-10-30 | 2022-03-02 | Personalis, Inc. | Methods for using mosaicism in nucleic acids sampled distal to their origin |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
AU2015353581A1 (en) | 2014-11-25 | 2017-06-15 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2016134078A1 (en) * | 2015-02-19 | 2016-08-25 | Becton, Dickinson And Company | High-throughput single-cell analysis combining proteomic and genomic information |
EP3262196B1 (en) | 2015-02-24 | 2020-12-09 | Adaptive Biotechnologies Corp. | Method for determining hla status using immune repertoire sequencing |
EP3261605B2 (en) | 2015-02-26 | 2022-04-20 | SiO2 Medical Products, Inc. | Cycloolefin polymer container with a scratch resistant and anti-static coating |
WO2016138496A1 (en) | 2015-02-27 | 2016-09-01 | Cellular Research, Inc. | Spatially addressable molecular barcoding |
ES2934982T3 (es) | 2015-03-30 | 2023-02-28 | Becton Dickinson Co | Métodos para la codificación con códigos de barras combinatorios |
EP3277294B1 (en) | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
EP3286326A1 (en) | 2015-04-23 | 2018-02-28 | Cellular Research, Inc. | Methods and compositions for whole transcriptome amplification |
MX2017013777A (es) * | 2015-04-27 | 2018-03-27 | Cancer Research Tech Ltd | Metodo para el tratamiento de cancer. |
US10568948B2 (en) * | 2015-05-13 | 2020-02-25 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
US11124823B2 (en) | 2015-06-01 | 2021-09-21 | Becton, Dickinson And Company | Methods for RNA quantification |
TWI750122B (zh) * | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
EP3328394A4 (en) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | PEPTIDE CONCATEMERIC EPITAOPE RNA |
GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
WO2017044574A1 (en) | 2015-09-11 | 2017-03-16 | Cellular Research, Inc. | Methods and compositions for nucleic acid library normalization |
JP6990176B2 (ja) | 2015-10-05 | 2022-02-03 | モデルナティエックス インコーポレイテッド | メッセンジャーリボ核酸薬物の治療投与のための方法 |
EP3362103A4 (en) * | 2015-10-12 | 2020-02-05 | Nantomics, LLC | COMPOSITIONS AND METHODS USING VIRAL CANCER NEOEPITOPES |
EP3362929B1 (en) * | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
CA3003090A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Cancer vaccines |
AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
CN105349533A (zh) * | 2015-12-21 | 2016-02-24 | 生工生物工程(上海)股份有限公司 | 构建链特异性转录组文库的方法 |
KR20180100659A (ko) * | 2016-01-08 | 2018-09-11 | 백시바디 에이에스 | 치료적 항암 네오에피토프 백신 |
WO2017118702A1 (en) * | 2016-01-08 | 2017-07-13 | Vaccibody As | Neoepitope rna cancer vaccine |
CN109563521A (zh) | 2016-03-24 | 2019-04-02 | 河谷细胞有限公司 | 用于新表位呈递的序列排列和序列 |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
US20190343942A1 (en) * | 2016-04-22 | 2019-11-14 | Curevac Ag | Rna encoding a tumor antigen |
EP4269616A3 (en) | 2016-05-02 | 2024-02-14 | Becton, Dickinson and Company | Accurate molecular barcoding |
WO2017190242A1 (en) * | 2016-05-04 | 2017-11-09 | Immunovaccine Technologies Inc. | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof |
US10301677B2 (en) | 2016-05-25 | 2019-05-28 | Cellular Research, Inc. | Normalization of nucleic acid libraries |
EP3465502B1 (en) | 2016-05-26 | 2024-04-10 | Becton, Dickinson and Company | Molecular label counting adjustment methods |
CA3025648A1 (en) * | 2016-05-27 | 2017-11-30 | Etubics Corporation | Neoepitope vaccine compositions and methods of use thereof |
US11299783B2 (en) | 2016-05-27 | 2022-04-12 | Personalis, Inc. | Methods and systems for genetic analysis |
US10640763B2 (en) | 2016-05-31 | 2020-05-05 | Cellular Research, Inc. | Molecular indexing of internal sequences |
US10202641B2 (en) | 2016-05-31 | 2019-02-12 | Cellular Research, Inc. | Error correction in amplification of samples |
WO2018011289A1 (en) * | 2016-07-13 | 2018-01-18 | Vaximm Ag | Process for the production of a dna vaccine for cancer immunotherapy |
AU2017299162A1 (en) * | 2016-07-20 | 2019-02-07 | BioNTech SE | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
AU2017331459B2 (en) | 2016-09-26 | 2023-04-13 | Becton, Dickinson And Company | Measurement of protein expression using reagents with barcoded oligonucleotide sequences |
US11164659B2 (en) | 2016-11-08 | 2021-11-02 | Becton, Dickinson And Company | Methods for expression profile classification |
CN117056774A (zh) | 2016-11-08 | 2023-11-14 | 贝克顿迪金森公司 | 用于细胞标记分类的方法 |
WO2018089637A1 (en) | 2016-11-11 | 2018-05-17 | Nantbio, Inc. | Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms |
CN108090325B (zh) * | 2016-11-23 | 2022-01-25 | 中国科学院昆明动物研究所 | 一种应用β-稳定性分析单细胞测序数据的方法 |
US20190369096A1 (en) * | 2017-01-13 | 2019-12-05 | Nantbio, Inc. | Validation of neoepitope-based treatment |
ES2961580T3 (es) | 2017-01-13 | 2024-03-12 | Cellular Res Inc | Revestimiento hidrófilo de canales de fluidos |
ES2971298T3 (es) * | 2017-01-18 | 2024-06-04 | Icahn School Med Mount Sinai | Neoantígenos y usos de los mismos para el tratamiento del cáncer |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
JP2020506189A (ja) * | 2017-02-01 | 2020-02-27 | モデルナティーエックス, インコーポレイテッド | Rna癌ワクチン |
CN110430894A (zh) * | 2017-02-01 | 2019-11-08 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
US11319583B2 (en) | 2017-02-01 | 2022-05-03 | Becton, Dickinson And Company | Selective amplification using blocking oligonucleotides |
CN110809716B (zh) | 2017-02-12 | 2023-07-07 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
US11938153B2 (en) | 2017-03-31 | 2024-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
AU2018258119B2 (en) | 2017-04-24 | 2021-04-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
AU2018266705B2 (en) | 2017-05-08 | 2023-05-04 | Gritstone Bio, Inc. | Alphavirus neoantigen vectors |
CA3062883C (en) | 2017-05-11 | 2024-04-02 | Theralase Biotech, Inc. | Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same |
CA3059559A1 (en) | 2017-06-05 | 2018-12-13 | Becton, Dickinson And Company | Sample indexing for single cells |
WO2018224166A1 (en) * | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
IL271558B2 (en) | 2017-06-21 | 2024-01-01 | Transgene | A vaccine tailored to the individual |
MX2020000414A (es) * | 2017-07-12 | 2020-09-28 | Nouscom Ag | Composicion de vacuna de neoantigeno para el tratamiento del cancer. |
US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
US20200354730A1 (en) * | 2017-11-27 | 2020-11-12 | Nantcell, Inc. | Improved Yeast Polytope Vaccine Compositions And Methods |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
TWI727232B (zh) * | 2017-12-01 | 2021-05-11 | 大陸商上海桀蒙生物技術有限公司 | 個人化癌症疫苗的製備方法 |
CA3083792A1 (en) * | 2017-12-18 | 2019-06-27 | Personal Genome Diagnostics Inc. | Machine learning system and method for somatic mutation discovery |
WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
WO2019126209A1 (en) | 2017-12-19 | 2019-06-27 | Cellular Research, Inc. | Particles associated with oligonucleotides |
MX2020007077A (es) | 2018-01-04 | 2020-10-28 | Iconic Therapeutics Inc | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. |
EP3766075A1 (en) * | 2018-03-14 | 2021-01-20 | Koninklijke Philips N.V. | System and method using local unique features to interpret transcript expression levels for rna sequencing data |
MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
US11365409B2 (en) | 2018-05-03 | 2022-06-21 | Becton, Dickinson And Company | Molecular barcoding on opposite transcript ends |
US11773441B2 (en) | 2018-05-03 | 2023-10-03 | Becton, Dickinson And Company | High throughput multiomics sample analysis |
IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neo-antigens |
CN112261947A (zh) * | 2018-05-25 | 2021-01-22 | 威斯塔研究所 | 肿瘤特异性新抗原和其使用方法 |
CN108897986B (zh) * | 2018-05-29 | 2020-11-27 | 中南大学 | 一种基于蛋白质信息的基因组序列拼接方法 |
US11814750B2 (en) | 2018-05-31 | 2023-11-14 | Personalis, Inc. | Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples |
US10801064B2 (en) | 2018-05-31 | 2020-10-13 | Personalis, Inc. | Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples |
EP3813848A4 (en) * | 2018-06-27 | 2022-07-20 | ModernaTX, Inc. | EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE |
JP2022511398A (ja) | 2018-10-01 | 2022-01-31 | ベクトン・ディキンソン・アンド・カンパニー | 5’転写物配列の決定 |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
CN114573688A (zh) * | 2018-10-19 | 2022-06-03 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
US20220125899A1 (en) * | 2018-11-07 | 2022-04-28 | Modernatx, Inc. | Rna cancer vaccines |
EP3877520A1 (en) | 2018-11-08 | 2021-09-15 | Becton Dickinson and Company | Whole transcriptome analysis of single cells using random priming |
US20210379170A1 (en) * | 2018-11-15 | 2021-12-09 | Nouscom Ag | Selection of cancer mutations for generation of a personalized cancer vaccine |
CN113195717A (zh) | 2018-12-13 | 2021-07-30 | 贝克顿迪金森公司 | 单细胞全转录组分析中的选择性延伸 |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
MX2021007556A (es) * | 2018-12-21 | 2021-09-10 | Biontech Us Inc | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. |
US11371076B2 (en) | 2019-01-16 | 2022-06-28 | Becton, Dickinson And Company | Polymerase chain reaction normalization through primer titration |
WO2020154247A1 (en) | 2019-01-23 | 2020-07-30 | Cellular Research, Inc. | Oligonucleotides associated with antibodies |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
US20220160850A1 (en) * | 2019-02-15 | 2022-05-26 | Rjan Holding Ab | Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine |
EP3940073A4 (en) | 2019-03-13 | 2023-03-01 | Toyobo Co., Ltd. | PRODUCTION AND AMPLIFICATION OF NUCLEIC ACIDS |
US11965208B2 (en) | 2019-04-19 | 2024-04-23 | Becton, Dickinson And Company | Methods of associating phenotypical data and single cell sequencing data |
CN112011833B (zh) * | 2019-05-30 | 2024-04-26 | 上海桀蒙生物技术有限公司 | 筛选和分离肿瘤新生抗原的方法 |
CA3140019A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
US11939622B2 (en) | 2019-07-22 | 2024-03-26 | Becton, Dickinson And Company | Single cell chromatin immunoprecipitation sequencing assay |
CN110277135B (zh) * | 2019-08-10 | 2021-06-01 | 杭州新范式生物医药科技有限公司 | 一种基于预期疗效选择个体化肿瘤新抗原的方法和系统 |
TWI793451B (zh) * | 2019-09-20 | 2023-02-21 | 納維再生科技股份有限公司 | 個人化癌症免疫治療 |
CN114729350A (zh) | 2019-11-08 | 2022-07-08 | 贝克顿迪金森公司 | 使用随机引发获得用于免疫组库测序的全长v(d)j信息 |
CN112795647B (zh) * | 2019-11-14 | 2022-08-16 | 北京肿瘤医院(北京大学肿瘤医院) | 一种肿瘤标志物及其应用 |
AU2020403145A1 (en) | 2019-12-13 | 2022-07-07 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
CN115244184A (zh) | 2020-01-13 | 2022-10-25 | 贝克顿迪金森公司 | 用于定量蛋白和rna的方法和组合物 |
WO2021184017A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ, インコーポレイテッド | 治療のための細胞外小胞 |
US11920202B2 (en) | 2020-04-09 | 2024-03-05 | University Of Connecticut | Unbiased identification of tumor rejection mediating neoepitopes |
US11661625B2 (en) | 2020-05-14 | 2023-05-30 | Becton, Dickinson And Company | Primers for immune repertoire profiling |
AU2021280261A1 (en) | 2020-05-26 | 2023-01-19 | Dionis Therapeutics, Inc. | Nucleic acid artificial mini-proteome libraries |
US11932901B2 (en) | 2020-07-13 | 2024-03-19 | Becton, Dickinson And Company | Target enrichment using nucleic acid probes for scRNAseq |
WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2022066898A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11739443B2 (en) | 2020-11-20 | 2023-08-29 | Becton, Dickinson And Company | Profiling of highly expressed and lowly expressed proteins |
JP2024501482A (ja) | 2020-12-14 | 2024-01-12 | ビオンテック ユーエス インコーポレイテッド | がん免疫療法のための組織特異的抗原 |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
WO2023076733A1 (en) | 2021-11-01 | 2023-05-04 | Dana-Farber Cancer Institute, Inc. | Biologically selected nucleic acid artificial mini-proteome libraries |
WO2023085232A1 (ja) | 2021-11-10 | 2023-05-19 | 東洋紡株式会社 | 改良されたライブラリー調製方法 |
CN114181287B (zh) * | 2021-12-10 | 2023-09-19 | 商丘美兰生物工程有限公司 | 一种dna病毒疫苗的制备方法 |
CN114350800B (zh) * | 2021-12-29 | 2024-03-19 | 中南大学湘雅医院 | Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用 |
CN114410778B (zh) * | 2021-12-29 | 2024-03-19 | 中南大学湘雅医院 | Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用 |
KR20230130804A (ko) * | 2022-03-04 | 2023-09-12 | (주)큐리진 | 순환종양세포 검출을 위한 아데노바이러스 5/3 형 |
EP4253550A1 (en) | 2022-04-01 | 2023-10-04 | GenCC GmbH 6 Co. KG | Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes |
WO2023209068A1 (en) | 2022-04-28 | 2023-11-02 | Carbocalyx Gmbh | Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
WO2024063788A1 (en) * | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064931A1 (en) * | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
DK0895538T3 (da) * | 1996-04-19 | 2002-11-04 | Us Gov Sec Health | Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter |
EP0900380B1 (en) | 1996-04-26 | 2003-07-09 | Rijksuniversiteit te Leiden | Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes |
WO1998010748A1 (en) | 1996-09-13 | 1998-03-19 | The School Of Pharmacy | Liposomes |
KR20000049096A (ko) * | 1996-10-11 | 2000-07-25 | 린다 에스. 스티븐슨 | 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법 |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
WO1999024566A1 (en) | 1997-11-06 | 1999-05-20 | Roche Diagnostics Gmbh | Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
WO1999034014A2 (en) | 1997-12-23 | 1999-07-08 | Roche Diagnostics Gmbh | A method for the determination of a nucleic acid |
WO1999034015A2 (en) * | 1997-12-24 | 1999-07-08 | Imperial Cancer Research Technology Limited | Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
JP2002526421A (ja) | 1998-10-05 | 2002-08-20 | ジェンザイム・コーポレーション | 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子 |
US6500641B1 (en) | 1999-05-06 | 2002-12-31 | Wake Forest University School Of Medicine | Compositions and methods for identifying antigens which elicit an immune response |
JP2003509035A (ja) | 1999-09-16 | 2003-03-11 | ザイコス インク. | ポリエピトープポリペプチドをコードする核酸 |
DE60038622D1 (de) * | 1999-10-20 | 2008-05-29 | Univ Johns Hopkins Med | Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure |
WO2001047959A2 (en) | 1999-11-30 | 2001-07-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
EP1242108B1 (en) | 1999-12-28 | 2007-07-11 | Pharmexa Inc. | Optimized minigenes and peptides encoded thereby |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
WO2001093902A2 (en) | 2000-06-07 | 2001-12-13 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
JP5087201B2 (ja) | 2000-08-03 | 2012-12-05 | ジョンズ・ホプキンス・ユニバーシティ | 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン |
US6472176B2 (en) | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
EP1800697B1 (de) | 2001-06-05 | 2010-04-14 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie |
WO2003046189A1 (en) | 2001-11-26 | 2003-06-05 | The University Of Queensland | Flavivirus vaccine delivery system |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
WO2003059381A2 (en) | 2002-01-18 | 2003-07-24 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
AU2002254010A1 (en) * | 2002-02-19 | 2003-09-09 | Genzyme Corporation | Par-3 compounds for therapy and diagnosis and methods for using same |
EP1485403A4 (en) * | 2002-03-15 | 2007-08-08 | Multicell Immunotherapeutics I | COMPOSITIONS AND METHOD FOR INTRODUCTION OR REINFORCEMENT OF ANTIBODY AND MAIN THISTOCOMPATIBILITY CLASS I OR CLASS II RESTRICTED T-CELL REACTIONS USING IMMUNOMODULATING, NON-CODING RNA MOTIVES |
ES2370688T3 (es) | 2002-06-13 | 2011-12-21 | Merck Patent Gmbh | Métodos para la identificación de alo-antígenos y su utilización para la terapia contra el cáncer y para el trasplante. |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
US20080063699A1 (en) | 2003-10-15 | 2008-03-13 | Michael Teifel | Method of Administering Cationic Liposomes Comprising an Active Drug |
ATE490470T1 (de) | 2003-10-24 | 2010-12-15 | Immunaid Pty Ltd | Therapieverfahren |
EP1589030A1 (en) * | 2004-04-14 | 2005-10-26 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Bob-1 specific T cells and methods to use |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
DE102004057303A1 (de) | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
SG158155A1 (en) | 2004-12-29 | 2010-01-29 | Mannkind Corp | Methods to bypass cd+4 cells in the induction of an immune response |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
LT2578685T (lt) | 2005-08-23 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai |
DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
WO2007101227A2 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
CA2647280A1 (en) | 2006-03-13 | 2007-09-20 | Veridex, Llc | Propagation of primary cells |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
EP2061504A4 (en) | 2006-09-20 | 2010-01-27 | Univ Johns Hopkins | COMBINATION THERAPY FOR CANCER AND INFECTION DISEASES WITH ANTI-B7-H1 ANTIBODIES |
DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
JP5623747B2 (ja) | 2006-12-27 | 2014-11-12 | エモリー ユニバーシティ | 感染症および腫瘍を処置するための組成物および方法 |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
DK2386557T3 (da) | 2008-03-24 | 2018-04-23 | Biontech Ag | Hidtil ukendte substituerede imidazoquinoliner |
US9789129B2 (en) | 2008-04-17 | 2017-10-17 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
JP5268444B2 (ja) * | 2008-06-23 | 2013-08-21 | 株式会社日立ハイテクノロジーズ | 単分子リアルタイムシーケンス装置,核酸分析装置及び単分子リアルタイムシーケンス方法 |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
WO2010042919A2 (en) | 2008-10-11 | 2010-04-15 | Government Of The U.S.A. , As Represented By The Secretary, Dpartmetn Of Health And Human Services | Method of making a vaccine |
CA2744449C (en) | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
EP2459231B1 (de) | 2009-07-31 | 2016-06-08 | Ethris Gmbh | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
ES2788863T3 (es) * | 2010-05-14 | 2020-10-23 | Massachusetts Gen Hospital | Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
DE102011102734A1 (de) | 2011-05-20 | 2012-11-22 | WMF Württembergische Metallwarenfabrik Aktiengesellschaft | Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch |
BR112013029834A8 (pt) | 2011-05-24 | 2022-10-18 | Biontech Ag | vacinas individualizadas para câncer |
RS59369B1 (sr) | 2011-05-24 | 2019-11-29 | Biontech Rna Pharmaceuticals Gmbh | Individualizovane vakcine protiv kancera |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
WO2013106496A1 (en) | 2012-01-10 | 2013-07-18 | modeRNA Therapeutics | Methods and compositions for targeting agents into and across the blood-brain barrier |
US9321808B2 (en) | 2012-02-20 | 2016-04-26 | Biontech Ag | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers |
US20130255281A1 (en) | 2012-03-29 | 2013-10-03 | General Electric Company | System and method for cooling electrical components |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
CN104662171B (zh) | 2012-07-12 | 2018-07-13 | 普瑟姆尼股份有限公司 | 个性化癌症疫苗和过继免疫细胞治疗 |
WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
AU2013337651B2 (en) | 2012-11-01 | 2018-12-13 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
EP3578663A1 (en) | 2013-03-15 | 2019-12-11 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
WO2014168874A2 (en) | 2013-04-07 | 2014-10-16 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3043826A4 (en) | 2013-09-13 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
JP6363179B2 (ja) | 2013-09-26 | 2018-07-25 | バイオンテック アーゲー | Rnaによるシェルを含む粒子 |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US20160264614A1 (en) | 2013-10-02 | 2016-09-15 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
WO2015085318A2 (en) | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
US20170007776A1 (en) | 2014-02-05 | 2017-01-12 | Biontech Ag | Cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device |
PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
EP4241784A3 (en) | 2014-12-12 | 2023-11-15 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
EP3240558A1 (en) | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
-
2012
- 2012-05-23 BR BR112013029834A patent/BR112013029834A8/pt not_active Application Discontinuation
- 2012-05-23 ES ES21168360T patent/ES2946072T3/es active Active
- 2012-05-23 MX MX2013013659A patent/MX360823B/es active IP Right Grant
- 2012-05-23 HU HUE21168360A patent/HUE062102T2/hu unknown
- 2012-05-23 RS RS20230380A patent/RS64230B1/sr unknown
- 2012-05-23 SI SI201231954T patent/SI3473267T1/sl unknown
- 2012-05-23 LT LTEP21168360.2T patent/LT3892295T/lt unknown
- 2012-05-23 RU RU2013157150A patent/RU2670745C9/ru active
- 2012-05-23 DK DK12723117.3T patent/DK2714071T3/da active
- 2012-05-23 PT PT181991050T patent/PT3473267T/pt unknown
- 2012-05-23 SG SG2013070727A patent/SG193553A1/en unknown
- 2012-05-23 ES ES12723117T patent/ES2746233T3/es active Active
- 2012-05-23 HU HUE12723117A patent/HUE046152T2/hu unknown
- 2012-05-23 WO PCT/EP2012/002209 patent/WO2012159754A2/en active Application Filing
- 2012-05-23 PT PT12723117T patent/PT2714071T/pt unknown
- 2012-05-23 CN CN201280029551.XA patent/CN103608033B/zh active Active
- 2012-05-23 ES ES18199105T patent/ES2897656T3/es active Active
- 2012-05-23 CN CN202010087649.7A patent/CN111286537A/zh active Pending
- 2012-05-23 AU AU2012261237A patent/AU2012261237B2/en active Active
- 2012-05-23 SI SI201232029T patent/SI3892295T1/sl unknown
- 2012-05-23 HU HUE18199105A patent/HUE057608T2/hu unknown
- 2012-05-23 NZ NZ742420A patent/NZ742420A/en unknown
- 2012-05-23 RS RS20211268A patent/RS62497B1/sr unknown
- 2012-05-23 DK DK21168360.2T patent/DK3892295T3/da active
- 2012-05-23 SG SG10201911616QA patent/SG10201911616QA/en unknown
- 2012-05-23 LT LTEP12723117.3T patent/LT2714071T/lt unknown
- 2012-05-23 NZ NZ730355A patent/NZ730355A/en unknown
- 2012-05-23 PT PT211683602T patent/PT3892295T/pt unknown
- 2012-05-23 FI FIEP21168360.2T patent/FI3892295T3/fi active
- 2012-05-23 US US14/119,348 patent/US10738355B2/en active Active
- 2012-05-23 LT LTEP18199105.0T patent/LT3473267T/lt unknown
- 2012-05-23 JP JP2014511773A patent/JP6444171B2/ja active Active
- 2012-05-23 PL PL21168360.2T patent/PL3892295T3/pl unknown
- 2012-05-23 CN CN201610330937.4A patent/CN105999250B/zh active Active
- 2012-05-23 HR HRP20230443TT patent/HRP20230443T1/hr unknown
- 2012-05-23 HR HRP20211595TT patent/HRP20211595T1/hr unknown
- 2012-05-23 CA CA2836494A patent/CA2836494C/en active Active
-
2013
- 2013-09-16 ZA ZA2013/06944A patent/ZA201306944B/en unknown
- 2013-11-22 MX MX2020011767A patent/MX2020011767A/es unknown
-
2016
- 2016-09-05 JP JP2016172519A patent/JP6456888B2/ja active Active
-
2017
- 2017-08-10 AU AU2017213515A patent/AU2017213515B2/en active Active
-
2018
- 2018-12-19 JP JP2018237242A patent/JP2019050831A/ja active Pending
-
2019
- 2019-09-13 AU AU2019229434A patent/AU2019229434B2/en active Active
-
2020
- 2020-05-22 JP JP2020089657A patent/JP7297715B2/ja active Active
- 2020-07-02 US US16/920,286 patent/US11248264B2/en active Active
-
2022
- 2022-01-14 US US17/576,170 patent/US20220282322A1/en active Pending
- 2022-02-24 AU AU2022201275A patent/AU2022201275A1/en active Pending
-
2023
- 2023-03-22 JP JP2023045776A patent/JP2023083289A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3892295T3 (da) | Individualiserede vacciner mod cancer | |
DK3275892T3 (da) | Præfusions-rsv-f-antigener | |
DK2768524T3 (da) | PD-L1-baseret immunterapi | |
DK2707030T3 (da) | Cancerbehandlinger | |
DK2793937T3 (da) | Vacciner mod HPV | |
DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
CO6960543A2 (es) | 2-tiopirimidinonas | |
DE102011100082A8 (de) | Traygreifvorrichtung | |
FI20115876A0 (fi) | Yhdistelmähoito | |
BR112014005756A2 (pt) | vacina | |
DK2686011T3 (da) | Ipn-vaccine | |
FI20115640A0 (fi) | Yhdistelmähoito | |
DK3473267T3 (da) | Individualiserede vacciner mod cancer | |
FR2972921B1 (fr) | Sucette orthodontique | |
ES2404690B1 (es) | Quitanieves avanzado | |
FR2974293B1 (fr) | Boitier orthodontique auto-ligaturant | |
DE102011117169A8 (de) | Absetzplattenanordnung | |
FI20105750A0 (fi) | Syöpärokote | |
DK2663304T3 (da) | Kombinationsterapi | |
FI9243U1 (fi) | Tyyny | |
UA22802S (uk) | Конверт | |
UA22660S (uk) | Конверт | |
UA22734S (uk) | Конверт | |
FI9358U1 (fi) | Eristetiiliharkko | |
UA22259S (uk) | Нашивка |